| Grudena, M. A., Davudova, T. B., Malisauskas, M., Zamotin, VV., Sewell, Robert David Edmund, Voskresenskaya, N. I., Kostanyan, I. A., Shrestnev, VV. and Morozova-Roche, L. A. 2004. Autoimmune responses to amyloid structures of A beta(25-35) peptide and human lysozyme in the serum of patients with progressive Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 18 (2) , pp. 165-171. 10.1159/000079197 |
Abstract
We have found an increased level of serum antibodies to the prefibrillar structures of both Abeta(25-35) peptide and human lysozyme in Alzheimer's disease (AD) patients compared to age-matched controls, indicating that autoimmunity is implicated in AD. In the serum of AD patients with a long-term duration (>15 years) the titer of serum antibodies to aggregates of Abeta(25-35) peptide increased by approximately 5-fold, whilst the antibody titer to lysozyme protofilaments decreased by approximately 8-fold compared to patients with AD duration of <5 years. The content of immunoglobulins of the A, G and M types declined, particularly in AD duration of >15 years. An increase in the concentration of immune complexes and higher lysozyme activity was detected in the serum of all patients and this was suggestive of an inflammatory reaction. We propose that the autoimmune response to different amyloid structures in AD can be viewed as a clearance pathway targeting amyloid development. Autoimmune response can be exploited as a marker of ongoing protein aggregation and hence be used as a diagnostic feature of AD.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | Published |
| Schools: | Schools > Pharmacy |
| Subjects: | R Medicine > RS Pharmacy and materia medica |
| Publisher: | Karger |
| ISSN: | 1420-8008 |
| Last Modified: | 04 Jun 2017 07:57 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/70492 |
Citation Data
Cited 56 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric